Bulk Manufacturer of Controlled Substances Application: American Radiolabeled Chem, 28152-28153 [2021-10996]
Download as PDF
<![CDATA[
28152
Federal Register / Vol. 86, No. 99 / Tuesday, May 25, 2021 / Notices
in the collection of data related to
pricing or other commercial terms.
Register pursuant to Section 6(b) of the
Act on January 28, 2021 (86 FR 7416).
Suzanne Morris,
Chief, Premerger and Division Statistics,
Antitrust Division.
Suzanne Morris,
Chief, Premerger and Division Statistics,
Antitrust Division.
[FR Doc. 2021–10934 Filed 5–24–21; 8:45 am]
[FR Doc. 2021–10925 Filed 5–24–21; 8:45 am]
BILLING CODE 4410–11–P
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–839]
Bulk Manufacturer of Controlled
Substances Application: American
Radiolabeled Chem
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Antitrust Division
Antitrust Division
jbell on DSKJLSW7X2PROD with NOTICES
Notice Pursuant to The National
Cooperative Research and Production
Act of 1993—Border Security
Technology Consortium
Notice is hereby given that, on April
23, 2021, pursuant to Section 6(a) of the
National Cooperative Research and
Production Act of 1993, 15 U.S.C. 4301
et seq. (‘‘the Act’’), Border Security
Technology Consortium (‘‘BSTC’’) has
filed written notifications
simultaneously with the Attorney
General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, Colvin Run Networks Inc.,
Leesburg, VA; DroneShield LLC,
Warrenton, VA; Pyramid Systems, Inc.,
Fairfax, VA; and Raytheon Company,
Waltham, MA have been added as
parties to this venture.
Also, Gatekeeper Inc., Sterling, VA;
Hamilton Sundstrand Corporation, San
Dimas, CA; Land Sea Air Autonomy,
Finksburg, MD; Mobilestack Inc, Dublin,
CA; and Priority 5 Holdings, Inc.,
Needham, MA have withdrawn as a
party to this venture. No other changes
have been made in either the
membership or planned activity of the
group research project. Membership in
this group research project remains
open, and BSTC intends to file
additional written notifications
disclosing all changes in membership.
On May 30, 2012, BSTC filed its
original notification pursuant to Section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to Section 6(b) of the
Act on June 18, 2012 (77 FR 36292).
The last notification was filed with
the Department on January 12, 2021. A
notice was published in the Federal
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Open Source Imaging
Consortium, Inc.
Notice is hereby given that, on May 5,
2021, pursuant to Section 6(a) of the
National Cooperative Research and
Production Act of 1993, 15 U.S.C. 4301
et seq. (‘‘the Act’’), Open Source
Imaging Consortium, Inc. (‘‘Open
Source Imaging Consortium’’) has filed
written notifications simultaneously
with the Attorney General and the
Federal Trade Commission disclosing
changes in its membership. The
notifications were filed for the purpose
of extending the Act’s provisions
limiting the recovery of antitrust
plaintiffs to actual damages under
specified circumstances. Specifically,
Pavilhao Pereira Filho Hospital, Porto
Alegre, BRAZIL; Medical University of
Vienna, Vienna, AUSTRIA; Royal
Brompton Hospital, London, UNITED
KINGDOM; The Research Institute of St.
Joseph’s, Ontario, CANADA; and
Thirona B.V., Nijmegen,
NETHERLANDS have been added as
parties to this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and Open Source
Imaging Consortium intends to file
additional written notifications
disclosing all changes in membership.
On March 20, 2019, Open Source
Imaging Consortium filed its original
notification pursuant to Section 6(a) of
the Act. The Department of Justice
published a notice in the Federal
Register pursuant to Section 6(b) of the
Act on April 12, 2019 (84 FR 14973).
The last notification was filed with
the Department on February 4, 2021. A
notice was published in the Federal
Register pursuant to Section 6(b) of the
Act on March 10, 2021 (86 FR 13751).
Suzanne Morris,
Chief, Premerger and Division Statistics,
Antitrust Division.
[FR Doc. 2021–10926 Filed 5–24–21; 8:45 am]
BILLING CODE 4410–11–P
VerDate Sep<11>2014
18:09 May 24, 2021
Jkt 253001
PO 00000
Frm 00100
Fmt 4703
Sfmt 4703
American Radiolabeled Chem
has applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before July 26, 2021. Such persons
may also file a written request for a
hearing on the application on or before
July 26, 2021.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on March 31, 2021,
American Radiolabeled Chem, 101 Arc
Drive, Saint Louis, Missouri 63146–
3502, applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substances:
SUMMARY:
Controlled substance
Gamma Hydroxybutyric Acid
Ibogaine ................................
Lysergic acid diethylamide ...
Tetrahydrocannabinols .........
Dimethyltryptamine ...............
1-[1-(2-Thienyl)
cyclohexyl]piperidine.
Dihydromorphine ...................
Heroin ...................................
Normorphine .........................
Amphetamine ........................
Methamphetamine ................
Amobarbital ...........................
Phencyclidine ........................
Phenylacetone ......................
Cocaine .................................
Codeine .................................
Dohydrocodeine ....................
Oxycodone ............................
Hydromorphone ....................
Ecgonine ...............................
Hydrocodone .........................
Meperidine ............................
Metazocine ............................
Methadone ............................
Dextropropoxyphene, bulk
(non-dosage forms).
Morphine ...............................
Oripavine ...............................
E:\FR\FM\25MYN1.SGM
25MYN1
Drug
code
Schedule
2010
7260
7315
7370
7435
7470
I
I
I
I
I
I
9145
9200
9313
1100
1105
2125
7471
8501
9041
9050
9120
9143
9150
9180
9193
9230
9240
9250
9273
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
9300
9330
II
II
Federal Register / Vol. 86, No. 99 / Tuesday, May 25, 2021 / Notices
Controlled substance
Thebaine ...............................
Oxymorphone .......................
Phenazocine .........................
Carfentanil .............................
Fentanyl ................................
Drug
code
9333
9652
9715
9743
9801
Schedule
II
II
II
II
II
The company plans to bulk
manufacture the listed controlled
substances for internal use or for sale to
its customers. The company plans to
manufacture small quantities of the
above-listed controlled substances as
radiolabeled compounds for
biochemical research. No other
activities for these drug codes are
authorized for this registration.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021–10996 Filed 5–24–21; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–838]
Importer of Controlled Substances
Application: SpecGX, LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
SpecGX, LLC. has applied to
be registered as an importer of basic
class(es) of controlled substance(s).
Refer to Supplemental Information
listed below for further drug
information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before June 24, 2021. Such persons
may also file a written request for a
hearing on the application on or before
June 24, 2021.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
jbell on DSKJLSW7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:09 May 24, 2021
Jkt 253001
In
accordance with 21 CFR 1301.34(a), this
is notice that on February 5, 2021,
SpecGX LLC, 3600 North 2nd Street,
Saint Louis, Missouri 63147, applied to
be registered as an importer of the
following basic class(es) of controlled
substance(s):
SUPPLEMENTARY INFORMATION:
Controlled substance
Marihuana ........................
Phenylacetone .................
Coca Leaves ...................
Thebaine ..........................
Opium, Raw .....................
Poppy Straw Concentrate
Tapentadol ......................
Drug
code
Schedule
7360
8501
9040
9333
9600
9670
9780
I
II
II
II
II
II
II
The company plans to import the
listed controlled substances for bulk
manufacture into Active Pharmaceutical
Ingredients (API) for distribution to its
customers. In reference to Tapentadol
(9780) and Thebaine (9333), the
company plans to import intermediate
forms of these controlled substances for
further manufacturing prior to
distribution to its customers. In
reference to drug code 7360
(Marihuana), the company plans to
import synthetic cannabinol. No other
activity for this drug is authorized for
this registration. Placement of these
codes onto the company’s registration
does not translate into automatic
approval of subsequent permit
applications to import controlled
substances.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend the
import of Food and Drug
Administration-approved or nonapproved finished forms for commercial
sale.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021–10995 Filed 5–24–21; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
[OMB Number 1105–0008]
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; Extension of a
Currently Approved Collection; Claim
for Damage, Injury, or Death
AGENCY:
Civil Division, Department of
Justice.
ACTION:
60-Day notice.
The Civil Division,
Department of Justice (DOJ), will be
SUMMARY:
PO 00000
Frm 00101
Fmt 4703
Sfmt 4703
28153
submitting the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
DATES: Comments are encouraged and
will be accepted for 60 days until July
26, 2021.
FOR FURTHER INFORMATION CONTACT:
Comments are encouraged and all
comments should reference the 8 digit
OMB number for the collection or the
title of the collection. If you have
questions concerning the collection,
please contact James G. Touhey, Jr.,
Director, Torts Branch, Civil Division,
U.S. Department of Justice, P.O. Box
888, Benjamin Franklin Station,
Washington, DC 20044, Telephone:
(202) 616–4400.
Written comments and/or suggestions
can also be directed to the Office of
Management and Budget, Office of
Information and Regulatory Affairs,
Attention Department of Justice Desk
Officer, Room 10235, 725 17th Street
NW, Washington, DC 20503 or sent to
OIRA_submissions@omb.eop.gov.
SUPPLEMENTARY INFORMATION: Written
comments and suggestions from the
public and affected agencies concerning
the proposed collection of information
are encouraged. Your comments should
address one or more of the following
four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Enhance the quality, utility, and
clarity of the information to be
collected; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
Overview of This Information
Collection
1. Type of Information Collection:
Extension of a currently approved
collection.
2. The Title of the Form/Collection:
Claim for Damage, Injury, or Death.
3. The agency form number, if any,
and the applicable component of the
E:\FR\FM\25MYN1.SGM
25MYN1
]]>Agencies
[Federal Register Volume 86, Number 99 (Tuesday, May 25, 2021)]
[Notices]
[Pages 28152-28153]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-10996]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-839]
Bulk Manufacturer of Controlled Substances Application: American
Radiolabeled Chem
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: American Radiolabeled Chem has applied to be registered as a
bulk manufacturer of basic class(es) of controlled substance(s). Refer
to Supplementary Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before July 26, 2021.
Such persons may also file a written request for a hearing on the
application on or before July 26, 2021.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on March 31, 2021, American Radiolabeled Chem, 101 Arc
Drive, Saint Louis, Missouri 63146-3502, applied to be registered as a
bulk manufacturer of the following basic class(es) of controlled
substances:
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid.............. 2010 I
Ibogaine............................... 7260 I
Lysergic acid diethylamide............. 7315 I
Tetrahydrocannabinols.................. 7370 I
Dimethyltryptamine..................... 7435 I
1-[1-(2-Thienyl)cyclohexyl]piperidine.. 7470 I
Dihydromorphine........................ 9145 I
Heroin................................. 9200 I
Normorphine............................ 9313 I
Amphetamine............................ 1100 II
Methamphetamine........................ 1105 II
Amobarbital............................ 2125 II
Phencyclidine.......................... 7471 II
Phenylacetone.......................... 8501 II
Cocaine................................ 9041 II
Codeine................................ 9050 II
Dohydrocodeine......................... 9120 II
Oxycodone.............................. 9143 II
Hydromorphone.......................... 9150 II
Ecgonine............................... 9180 II
Hydrocodone............................ 9193 II
Meperidine............................. 9230 II
Metazocine............................. 9240 II
Methadone.............................. 9250 II
Dextropropoxyphene, bulk (non-dosage 9273 II
forms).
Morphine............................... 9300 II
Oripavine.............................. 9330 II
[[Page 28153]]
Thebaine............................... 9333 II
Oxymorphone............................ 9652 II
Phenazocine............................ 9715 II
Carfentanil............................ 9743 II
Fentanyl............................... 9801 II
------------------------------------------------------------------------
The company plans to bulk manufacture the listed controlled
substances for internal use or for sale to its customers. The company
plans to manufacture small quantities of the above-listed controlled
substances as radiolabeled compounds for biochemical research. No other
activities for these drug codes are authorized for this registration.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021-10996 Filed 5-24-21; 8:45 am]
BILLING CODE P
